13F GuideFiling Basics
What is SEC Form 13F? Ultimate Guide to Institutional Equity Filings
Learn how SEC Form 13F filings work, the $100M threshold, 45-day reporting lag, and how to track top hedge fund holdings.
AlphaSMO Research GuideRead Guide
CIK: 0001703031
Total reported value
$1.7B
$1.7B
24 檔
40.6%
As reported in its official Q3 2024 Form 13F filing, Bain Capital Life Sciences Investors, LLC's tracked investment portfolio stood at $1.7B with 24 total positions.
In Q3 2024, Bain Capital Life Sciences Investors, LLC displayed an active expansion posture, initiating 1 new positions and adding to 5 existing holdings, outstripping position reductions.
| # | Ticker | Issuer | Asset Subclass | Weight | Weight Change | Shares Change | 4Q Trend |
|---|---|---|---|---|---|---|---|
| 1 | NUVL | Nuvalent Inc-a | Stock-Other | 28.71% | — | — | |
| 2 | NAMS | NewAmsterdam Pharma Company N.V. | Stock-Other | 18.09% | -13.42% | — | |
| 3 | IRON | Disc Medicine Inc | Stock-Other | 9.18% | -0.20% | — | |
| 4 | DNTH | Dianthus Therapeutics Inc | Stock-Other | 8.58% | -0.64% | — | |
| 5 | SVRA | Savara Inc | Stock-Other | 6.43% | -2.22% | — | |
| 6 | PHVS | Pharvaris N.V. | Stock-Other | 6.36% | -1.32% | — | |
| 7 | ANNX | Annexon Inc | Stock-Other | 5.20% | -1.09% | +0.01% | |
| 8 | SLDB | Solid Biosciences Inc | Stock-Other | 2.93% | -0.54% | — | |
| 9 | TNGX | Tango Therapeutics Inc | Stock-Other | 2.17% | — | -6.25% | |
| 10 | KYTX | Kyverna Therapeutics Inc | Stock-Other | 1.71% | -0.89% | — | |
| 11 | ✓ | Mersana Therapeutics Inc | Stock-Other | 1.70% | — | — | |
| 12 | CABA | Cabaletta Bio Inc | Stock-Other | 1.36% | +0.84% | +67.33% | |
| 13 | ASNSUSD | X4 Pharmaceuticals Inc | Stock-Other | 1.18% | — | — | |
| 14 | IPSC | Century Therapeutics Inc | Stock-Other | 0.96% | — | — | |
| 15 | AVIR | Atea Pharmaceuticals Inc | Stock-Other | 0.87% | -0.58% | — | |
| 16 | CDTX | Cidara Therapeutics Inc | Stock-Other | 0.79% | — | — | |
| 17 | RPID | Rapid Micro Biosystems Inc-a | Stock-Other | 0.78% | -0.86% | — | |
| 18 | CCCC | C4 Therapeutics Inc | Stock-Other | 0.66% | +0.29% | — | |
| 19 | SYRS | Syros Pharmaceuticals Inc | Stock-Other | 0.62% | — | +0.01% | |
| 20 | NAUT | Nautilus Biotechnology Inc | Stock-Other | 0.59% | — | — | |
| 21 | MRNS* | Marinus Pharmaceuticals Inc | Stock-Other | 0.49% | — | +18.77% | |
| 22 | ✓ | Xilio Therapeutics Inc | Stock-Other | 0.37% | — | +20.64% | |
| 23 | IVVD | Invivyd Inc | Stock-Other | 0.19% | — | — | |
| 24 | ✓ | Newamsterdam Pharma Company | Stock-Other | 0.07% | -0.05% | — |
| # | Ticker | Issuer | Weight Change | Shares Change | Action |
|---|---|---|---|---|---|
| 1 | NUVL | Nuvalent Inc-a | +6.3% | — | Unchanged |
| 2 | CDTX | Cidara Therapeutics Inc | +0.8% | NEW | New buy |
| 3 | ANNX | Annexon Inc | +0.7% | +0.01% | Add |
| 4 | SLDB | Solid Biosciences Inc | +0.4% | — | Unchanged |
| 5 | IRON | Disc Medicine Inc | +0.3% | — | Unchanged |
| 6 | MRNS* | Marinus Pharmaceuticals Inc | +0.2% | +18.77% | Add |
| 7 | RPID | Rapid Micro Biosystems Inc-a | +0.2% | — | Unchanged |
| 8 | ASNSUSD | X4 Pharmaceuticals Inc | +0.1% | — | Unchanged |
| 9 | CCCC | C4 Therapeutics Inc | +0.1% | — | Unchanged |
| 10 | NAUT | Nautilus Biotechnology Inc | +0.1% | — | Unchanged |
| 11 | DNTH | Dianthus Therapeutics Inc | 0% | — | Unchanged |
| 12 | CABA | Cabaletta Bio Inc | — | +67.33% | Add |
| 13 | SVRA | Savara Inc | 0% | — | Unchanged |
| 14 | ✓ | Xilio Therapeutics Inc | 0% | +20.64% | Add |
| 15 | ✓ | Newamsterdam Pharma Company | 0% | — | Unchanged |
| 16 | IVVD | Invivyd Inc | 0% | — | Unchanged |
| 17 | AVIR | Atea Pharmaceuticals Inc | 0% | — | Unchanged |
| 18 | ACRS | Aclaris Therapeutics Inc | -0.1% | EXIT | Sold out |
| 19 | ✓ | Mersana Therapeutics Inc | -0.2% | — | Unchanged |
| 20 | PHVS | Pharvaris N.V. | -0.5% | — | Unchanged |
| 21 | IPSC | Century Therapeutics Inc | -0.6% | — | Unchanged |
| 22 | TNGX | Tango Therapeutics Inc | -0.6% | -6.25% | Trim |
| 23 | SYRS | Syros Pharmaceuticals Inc | -0.9% | +0.01% | Add |
| 24 | ARQT | Arcutis Biotherapeutics Inc | -1.1% | EXIT | Sold out |
| 25 | KYTX | Kyverna Therapeutics Inc | -1.1% | — | Unchanged |
| 26 | NAMS | NewAmsterdam Pharma Company N.V. | -4% | — | Unchanged |
According to official SEC Form 13F filings, Bain Capital Life Sciences Investors, LLC reported a total U.S. public equity portfolio value of $1.7B across 24 disclosed positions in Q3 2024.
Expert Analysis & Guides for Tracking Wall Street Smart Money Movements
Learn how SEC Form 13F filings work, the $100M threshold, 45-day reporting lag, and how to track top hedge fund holdings.
In terms of portfolio concentration, the top 5 core holdings (including NUVL, NAMS, IRON) accounted for 40.6% of total reported equity market value during Q3 2024.
Top New Position Initiated
CDTX
市值: $7.6M
Top Position Liquidated / Trimmed
ARQT
前期市值: $9.6M
During Q3 2024, Bain Capital Life Sciences Investors, LLC's top holdings by market value included NUVL (28.7%)、NAMS (18.1%)、IRON (9.2%). The largest single position, NUVL, represented 28.7% of total portfolio value.
In Q3 2024, Bain Capital Life Sciences Investors, LLC made 9 total portfolio adjustments, initiating 1 new buys, adding to 5 positions, trimming 1 holdings, and fully liquidating 2 stocks.
All holding records on this page are fetched directly from the U.S. Securities and Exchange Commission (SEC) EDGAR system (Form 13F-HR). AlphaSMO parses CUSIP identifiers and formats data into Schema.org-compliant datasets.
Understand SEC Form 4 insider disclosures for corporate officers, directors, and 10% owners to track executive transactions.
Understand Rule 144 restricted stock sale notices to spot planned insider liquidations before market sell pressure arrives.
Explore the 5% beneficial ownership threshold, 13D vs 13G filing differences, and recent SEC accelerated deadline rules.
Best practices for analyzing 13F quarterly changes without getting misled by stock splits, options, or market valuation drift.
Learn how AlphaSMO's flagship signal detects high-conviction stocks where 13F hedge funds and corporate insiders buy at the same time.